N-Acetyl-cysteine inhibits phospholipid metabolism, proinflammatory cytokine release, protease activity, and nuclear factor-kappaB deoxyribonucleic acid-binding activity in human fetal membranes in vitro

J Clin Endocrinol Metab. 2003 Apr;88(4):1723-9. doi: 10.1210/jc.2002-021677.

Abstract

The production of reactive oxygen species (ROS), prostaglandins (PGs), proinflammatory cytokines, and proteases has been implicated in the pathogenesis of term and preterm labor. The nuclear factor-kappaB (NF-kappaB) transcription pathway is activated by ROS and is a key regulator of PGs, proinflammatory cytokine release, and protease activity. N-Acetyl-cysteine (NAC) is an antioxidant that through its ability to scavenger ROS suppresses NF-kappaB DNA-binding activity and resultant gene expression. The aim of this study was to elucidate the effect of NAC on NF-kappaB DNA-binding activity, phospholipid metabolism, cytokine release, and protease activity from human fetal membranes. Human amnion and choriodecidua (n = 9 separate placentas) were treated with 0 (control), 5, 10, or 15 mM NAC in the presence of 10 micro g/ml lipopolysaccharide. After 6-h incubation, the tissues were collected, NF-kappaB DNA binding activity was assessed by gel shift binding assays, and matrix metalloproteinase-9 and urokinase-type plasminogen activator activity were determined by zymography. The incubation medium was collected and assayed for type II phospholipase A(2) tissue content, IL-6, IL-8, TNFalpha, and 8-isoprostane release by ELISA. The release of PGF(2alpha) was measured by RIA. Treatment of fetal membranes with NAC significantly suppressed lipopolysaccharide-stimulated type II phospholipase A(2) release and content; PGF(2alpha), IL-6, IL-8, TNFalpha, and 8-isoprostane release; and matrix metalloproteinase-9 and urokinase-type plasminogen activator enzyme activity and suppressed NF-kappaB DNA-binding activity (by ANOVA, P < 0.05). The data presented in this study demonstrate that NAC inhibits an NF-kappaB-activated pathway and subsequent phospholipid metabolism, proinflammatory cytokine release, and protease activity in human fetal membranes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / pharmacology*
  • Amnion / drug effects
  • Amnion / metabolism
  • Chorion / drug effects
  • Chorion / metabolism
  • Culture Techniques
  • Cytokines / metabolism*
  • DNA / metabolism
  • Decidua / drug effects
  • Decidua / metabolism
  • Dinoprost / metabolism
  • Endopeptidases / metabolism*
  • Extraembryonic Membranes / drug effects*
  • Extraembryonic Membranes / metabolism
  • F2-Isoprostanes / metabolism
  • Female
  • Humans
  • Interleukin-6 / metabolism
  • Interleukin-8 / metabolism
  • L-Lactate Dehydrogenase / metabolism
  • Matrix Metalloproteinase 9 / metabolism
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / metabolism*
  • Oxidative Stress
  • Phospholipases A / antagonists & inhibitors
  • Phospholipases A / metabolism
  • Phospholipids / metabolism*
  • Pregnancy
  • Urokinase-Type Plasminogen Activator / metabolism

Substances

  • Cytokines
  • F2-Isoprostanes
  • Interleukin-6
  • Interleukin-8
  • NF-kappa B
  • Phospholipids
  • 8-epi-prostaglandin F2alpha
  • DNA
  • Dinoprost
  • L-Lactate Dehydrogenase
  • Phospholipases A
  • Endopeptidases
  • Urokinase-Type Plasminogen Activator
  • Matrix Metalloproteinase 9
  • Acetylcysteine